Although every cell in the human body shares an identical genome, most genes are only activated in specific cell types, at particular developmental stages, or in response to certain stimulati. To organize and manage genetic information and enable cellular specification, nature has evolved sophisticated mechanisms that facilitate the precise and regulated activation of genes.
Our laboratory focuses on the processes that orchestrate cell type-specific gene regulation during cellular differentiation. We investigate the interplay between transcription factors and epigenetic mechanisms, particularly DNA methylation, in regulating hematopoietic lineage specification and the development of leukemia.
Our collaborative study on the fate, phenotype, and clinical efficacy of ex vivo expanded and co-transplanted donor regulatory T cells were published in Nature Communications.
Claudia's studies on the effects of STAG2 mutations in AML and our characterization of CIMP-AML were published in Cell Reports and Nature Communications. Both very fruitful collaborations with Ruud Delwels group in Rotterdam.
We are looking for a motivated PhD student to work on our exciting new DFG project on de novo enhancer function. Ready to join our group?
Our group operates the Sequencing Core at the Leibniz Institute for Immunotherapy (LIT). We provide a comprehensive array of services to the local scientific community, including consultation, library preparation (with a focus on single-cell applications), and sequencing services.
For more information visit the NGS Core Website.
Michael Rehli • Dept. Internal Medicine III • University Hospital
F.-J.-Strauss Allee 11 • 93053 Regensburg • Germany
Imprint & Privacy